Items where authors include "Usmani, SZ"

Export as [feed] Atom [feed] RSS
Number of items: 11.


Thompson, MA, Boccadoro, M, Leleu, X et al. (26 more authors) (2023) Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients. Clinical Lymphoma Myeloma and Leukemia, 23 (3). e171-e181. ISSN 2152-2650

San-Miguel, JF, Avet-Loiseau, H, Paiva, B et al. (24 more authors) (2022) Sustained Minimal Residual Disease Negativity With Daratumumab in Newly Diagnosed Multiple Myeloma: MAIA and ALCYONE. Blood, 139 (4). pp. 492-501. ISSN 0006-4971

Hájek, R, Minařík, J, Straub, J et al. (33 more authors) (2021) Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma. Future Oncology. fon-2020-1225. ISSN 1479-6694

Moreau, P, Kumar, SK, San Miguel, J et al. (67 more authors) (2021) Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. The Lancet Oncology, 22 (3). e105-e118. ISSN 1470-2045

Terpos, E, Mikhael, J, Hajek, R et al. (13 more authors) (2021) Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. Blood Cancer Journal, 11 (2). 40. ISSN 2044-5385

Kaufman, JL, Dimopoulos, MA, White, D et al. (26 more authors) (2020) Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX. Blood Cancer Journal, 10 (11). 111. ISSN 2044-5385

Mateos, M-V, Spencer, A, Nooka, AK et al. (16 more authors) (2019) Daratumumab-Based Regimens Are Highly Effective And Well Tolerated In Relapsed Or Refractory Multiple Myeloma Regardless Of Patient Age: Subgroup Analysis Of The Phase 3 CASTOR And POLLUX Studies. Haematologica. ISSN 0390-6078

Costello, C, Davies, FE, Cook, G et al. (16 more authors) (2019) INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma. Future Oncology, 15 (13). pp. 1411-1428. ISSN 1479-6694

Dimopoulos, MA, San-Miguel, J, Belch, A et al. (30 more authors) (2018) Daratumumab Plus Lenalidomide And Dexamethasone Versus Lenalidomide And Dexamethasone In Relapsed Or Refractory Multiple Myeloma: Updated Analysis Of POLLUX. Haematologica, 103 (12). pp. 2088-2096. ISSN 0390-6078

Conference or Workshop Item

Kaufman, JL, Usmani, SZ, San-Miguel, J et al. (16 more authors) (2020) Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM). In: 61st American Society of Hematology (ASH) Annual Meeting, 07-10 Dec 2019, Orlando, Florida, USA.

Proceedings Paper

Hajek, R, Terpos, E, Lee, HC et al. (20 more authors) (2018) Ixazomib Plus Lenalidomide-Dexamethasone (IRd) in Relapsed/Refractory Multiple Myeloma (MM) Patients (Pts) - Effectiveness in Routine Clinical Practice Is Similar to the Efficacy in the Phase 3 Tourmaline-MM1 Trial: A Pooled Analysis from the Insight MM Observational Study and the Czech Registry of Monoclonal Gammopathies (RMG). In: Blood. ASH 2018 – 60th American Society of Hematology Annual Meeting and Exposition, 01-04 Dec 2018, San Diego, CA. American Society of Hematology .

This list was generated on Sun Mar 3 23:36:16 2024 GMT.